Methods for determining toxicity reversing agents

• US 6,723,527 B2
• Filed: 10/26/2001
• Issued: 04/20/2004
• Est. Priority Date: 10/26/2001
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Pettit, Flora H., Shive, William
• Primary Examiner(s): Leary, Louise N.
• Application Number:
  US10/010,716
• Publication Number:
  US 20030087331A1
• Time in Patent Office: 907 Days
• Field of Search: 435/29, 435/7.2, 435/7.24, 435/4, 424/900
• US Class Current: 435/29
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5047 Cells of the immune system
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: Y10S 424/90 In vivo diagnostic or in vivo test agent which contains an additional ingredient to reduce the toxicity or side effects of the active ingredient

Abstract

Disclosed are methods for assessment of the ability of substances to ameliorate the toxic-effects of compounds based on a lymphocyte culture assay. The lymphocyte assay is a repeatable and quantitative assay for lymphocyte growth in a chemically defined media in which specific compounds with potential toxicity and substances with potential abilities to ameliorate the toxicity can be added to determine specific and individualized requirements for such substances. Also disclosed are methods for ameliorating side-effects by administering to a patient undergoing therapy with a drug that has a toxic-effect, a substance identified by the methods of the invention. Further provided is a composition that ameliorates the toxic-effect of the statin family of drugs. Methods and processes for partially purifying and/or isolating this composition are also provided. Thus, the methods of the invention not only provide substances for reversal of compound-toxicity but also provide methods for pre-approving compounds for human use.

Claims

1. A method for testing a substance for the ability of the substance to ameliorate the toxic-effects of a compound, comprising the steps of:

a) incubating lymphocytes in the presence of the compound and in the presence and absence of the substance; and

b) comparing the toxic-effect of the compound on the lymphocytes incubated in the presence of the substance to the effect of the compound on the lymphocytes in the absence of the substance, wherein the toxic-effect of the compound is assessed by assessing its effect on the amount of ATP synthesized by the lymphocytes.

2. The method of claim 1, wherein the amount of ATP synthesized is measured by fluorimetric methods.

3. The method of claim 1, further comprising determining the lowest dosage at which a substance can ameliorate the toxic effect of said compound.

4. The method of claim 1, wherein the compound is a clinical drug, a teratogenic agent, a social drug, a drug additive, a food additive, a food component, an herb, an herbal extract, or a chemical compound.

5. The method of claim 1, wherein the compound is comprised in a plant or a mushroom.

6. The method of claim 4, wherein the clinical drug is a metabolic inhibitor.

7. The method of claim 6, wherein said metabolic inhibitor is a stalin.

8. The method of claim 7, wherein said statin is lip itor, mevacor, pravachol, zocor, Baychol, Cerivastatin, or Fluvastatin.

9. The method of claim 4, wherein the clinical drug is a sedative.

10.The method of claim 9, wherein the sedative is diazepam.

10. The method of claim 4, where the clinical drug is a chemotherapeutic agent.

12. The method of claim 4, wherein the clinical drug is an anti-inflammatory agent.

17. The method of claim 4, wherein the clinical drug is isoniazid.

19. The method of claim 4, wherein the clinical drug is retinol.

20. The method of claim 4, wherein the teratogenic agent is thalidomide.

21. The method of claim 4, wherein the food additive is monosodium glutamate, aspartame or saccharin.

22. The method of claim 4, wherein the chemical compound comprises a metal.

25. The method of claim 4, wherein the social drug comprises ethanol, theophylline, caffeine or theobromine.

26. The method of claim 1, wherein the substance is a nutritional supplement, a protein, a peptide, an amino acid, a chemical, a biochemical, a small molecule, or a pharmaceutical agent.

27. The method of claim 1, wherein the substance is LDL.

28. The method of claim 1, further comprising a control comprising:

a) incubating the lymphocytes with a compound with a known toxicity in the presence of a substance known to reverse said known toxicity; and

b) analyzing the effect on lymphocytes.

29. A method for ameliorating toxicity in a patient undergoing therapy with a compound that has a known toxicity comprising, administrating to said patient a substance identified in accordance with the method of claim 1.

37. The method of claim 1, wherein said lymphocytes are further incubated in a chemically defined medium.

38. The method of claim 1, wherein the toxic-effect of the compound is assessed by assessing the effect of said compound on the growth of the lymphocytes.

39. The method of claim 1, wherein the toxic-effect of the compound is assessed by assessing the effect of said compound on the cell-size of the lymphocytes.

40. The method of claim 1, wherein the toxic-effect of the compound is assessed by assessing the effect of said compound on the morphology of the lymphocytes.

11. The method of claim 11, wherein the chemotherapeutic agent is methotrexate, 5-fluorouracil, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, plicomycin, taxol, vincristine, vinbiastine, cisplatin, VP16, carmustine, meiphalan, cyclophosphamide, chlorambucil, busulfan, lomustine, carboplatin, procarbazine, mechiorethamine, camptothecin, ifosfamide, nitrosurea, tamoxifen, raloxifene, estrogen receptor binding agents, gemcitabien, navelbine, farnesyl-protein transferase inhibitors, transpiatinum or temazolomide.

13. The method of claim 13, wherein the anti-inflammatory agent comprises salicylate and/or acetyl salicylate.

15. The method of claim 13, wherein the anti-inflammatory agent comprises a steroid.

14. The method of claim 14, where the anti-inflammatory agent is ibuprofen, ketoprofen, piroxicam, naproxen, naproxen sodium, sulindac, aspirin, choline subsalicylate, diflunisal, oxaprozin, diclofenac sodium delayed release, diclofenac potassium immediate release, etodolac, ketorolac, fenoprofen, flurbiprofen, indomethacin, fenamates, meclofenamate, mefenamic acid, nabumetone, oxicam, piroxicam, salsalate, tolmetin, or magnesium salicylate.

16. The method of claim 16, wherein the steroid is dexamethason, hydrocortisone, methylprednisolone, prednisone, or triamcinolone.

18. The method of clain 4, wherein the clinical drug is valproic acid.

23. The method of claim 23, wherein the metal is aluminum.

24. The method of claim 23, wherein the metal is copper.

30. The method of claim 30, wherein said patient is human patient.

31. A method for ameliorating toxicity in a patient undergoing therapy with a compound that has a known toxicity comprising:

a) isolating lymphocytes from said patient;

b) incubating lymphocytes in the presence of the compound and in the presence and absence of a candidate substance that can reverse the toxicity of said compound;

c) comparing the toxic-effect of the compound on the lymphocytes incubated in the presence of the candidate substance to the effect of the compound on the lymphocytes in the absence of the candidate substance thereby identifying a substance that can reverse toxicity. wherein the toxic-effect of the compound is assessed by assessing its effect on the amount of ATP synthesized by the lymphocytes; and

d) administrating to said patient the identified substance that can reverse toxicity of the compound.

32. The method of claim 32, wherein said patient is human patient.

33. A composition comprising one or more factors characterized by the following properties:

a) isolatable from mammalian plasma;

b) containing at least one heat-labile component having a molecular weight of at least 100,000; and

c) having the ability to ameliorate the toxicity of a metabolic inhibitor.

34. The composition of claim 34, wherein the mammalian plasma is human plasma.

35. The composition of claim 34, wherein said metabolic inhibitor is a statin.

36. The composition of claim 36, wherein said statin is lipitor, mevacor, pravachol, zocor, Baychol, Cerivastatin, or Fluvastatin.